Baxalta Gmbh

The State University of New York

Brookhaven Science Associates, Lcc

Baxter International Inc.

Baxter Healthcare Sa

Hookipa Biotech Gmbh

Takeda Pharmaceuticals International Ag

Michael Schwendinger

Ian Livey

Brian A Crowe

Maria O'Rourke

John J Dunn

Benjamin J Luft

Thomas P Monath

Katherine Cohen

Sarah Schmidt

Anders Lilja

Klaus Orlinger

Gerhard Fuhrmann

Andreas Aspöck

Elizabeth Watson

Bettina Kiefmann

Ursula Berka

Julia Hinteramskogler

Maria O'rourke

Ian Dr Livey

Benjamiin J Luft

Provided herein are genetically modified arenaviruses suitable as vaccines against neoplastic diseases or cancer. The invention also relates to pharmaceutical compositions and methods for the prevention or treatment of certain infections causing neoplastic diseases or cancer, such as infections with oncogenic viruses. Specifically, provided herein are pharmaceutical compositions, vaccines, and methods of preventing or treating diseases and conditions caused by and associated with infections with Human Papillomavirus (HPV), such as cervical cancer, anogenital cancer, head and neck cancer and skin cancers. Also provided herein are immunotherapies for the treatment of a neoplastic disease, such as a neoplastic disease caused by infection with oncogenic viruses.

HPV vaccines

The invention relates to the development of chimeric OspA molecules for use in a new Lyme vaccine. More specifically, the chimeric OspA molecules comprise the proximal portion from one OspA serotype, together with the distal portion from another OspA serotype, while retaining antigenic properties of both of the parent polypeptides. The chimeric OspA molecules are delivered alone or in combination to provide protection against a variety ofgenospecies. The invention also provides methods for administering the chimeric OspA molecules to a subject in the prevention and treatment of Lyme disease or borreliosis.

Chimeric OspA genes, proteins and methods of use thereof

Chimeric OspA proteins and methods of use thereof

Chimeric OspA genes, proteins, and methods of use thereof

The invention relates to the development of chimeric OpsA molecules for use in a new Lyme vaccine. More specifically, the chimeric OspA molecules comprise the proximal portion from one OspA serotype, together with distal portion from another OspA serotype, while retaining antigenic properties of both of the parent polypeptides. The chimeric OspA molecules are delivered alone or in combination to provide protection against a variety ofgenospecies. The invention also provides methods for administering the chimeric OspA molecules to a subject in the prevention and treatment of Lyme disease or borreliosis.

Growing community of inventors

Neusiedl am See, Austria

Michael Schwendinger